Pharmacyte Biotech Inc (OTCMKTS:PMCB) announced the list of major milestone tasks that it plans to achieve before it begins its Phase IIB trial in pancreatic cancer. The company stated it will have a clinical protocol that will be designed in coordination with Contract Research Organization and its team of oncologists. This designed protocol can be considered as a “recipe” on how the trials will be performed.
The main factors that will be included in protocol are the qualifications required for particular patients to be enrolled in the study, the mode of use of Pharmacyte’s treatment in the “comparator” arm of the trial and the duration and schedule of these treatments, the specific “endpoints” for the clinical study and the data types that will be collected to assess these endpoints; and the types of data analysis to be used while conducting trial.
In last trading session, the stock price of Pharmacyte jumped more than 3% to close the week at $0.0910.
Natural Alternatives International, Inc. (NASDAQ:NAII) Files Complaint Against Creative Compounds Inc.
Natural Alternatives International, Inc. (NASDAQ:NAII) submitted a Complaint against Creative Compounds Inc. to stop it from improperly and intentionally trying to mislead company’s potential and actual clients and wrongfully interfering with its CarnoSyn® beta-alanine business.
Natural Alternatives offers beta-alanine to clients under the trademark CarnoSyn® and it owns a portfolio of 34 patents in the U.S. and foreign countries related to beta-alanine. In various scientific trials, CarnoSyn® beta-alanine, when utilized as a dietary supplement, has been validated to defer the fatigue onset in muscle cells, thus eliminating muscle soreness and fatigue. It has been demonstrated to enhance athletic performance.
The company alleged that, on or near to September 5, Creative Compounds sent an internet communication to clients and potential clients of beta-alanine making various misleading and false statements pertaining to Creative’s generic beta-alanine, Natural Alternatives’ CarnoSyn® beta-alanine, and its intellectual property rights.
Uluru Inc (OTCMKTS:ULUR) posted strong session on Friday and jumped more than 38% to close the week at $0.388.